Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 250 of 254 entries
View as:

A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.

Phase: N/A Priority: Normal
NCT ID: NCT01283100 Org: User:
Start: 03/31/11 End: 06/30/11 Due: 06/30/12

A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

Phase: N/A Priority: Normal
NCT ID: NCT00801515 Org: User:
Start: 08/31/09 End: 07/31/11 Due: 07/31/12

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

Phase: N/A Priority: Normal
NCT ID: NCT02362503 Org: User:
Start: 02/23/15 End: 12/31/25 Due: 12/31/26

Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

Phase: N/A Priority: Normal
NCT ID: NCT03016533 Org: User:
Start: 06/07/17 End: 12/24/24 Due: 12/24/25

Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529

Phase: N/A Priority: Normal
NCT ID: NCT02164045 Org: User:
Start: 06/24/14 End: 07/25/14 Due: 07/25/15

Food Effect Study With BMS-955176

Phase: N/A Priority: Normal
NCT ID: NCT02273947 Org: User:
Start: 10/23/14 End: 08/15/16 Due: 08/15/17

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT06012136 Org: User:
Start: 08/24/23 End: 09/02/26 Due: 09/02/27

Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

Phase: N/A Priority: Normal
NCT ID: NCT01568892 Org: User:
Start: 04/18/12 End: 12/16/13 Due: 12/16/14

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02859259 Org: User:
Start: 08/12/16 End: 08/12/16 Due: 08/12/17

Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02478463 Org: User:
Start: 02/27/17 End: 07/25/19 Due: 07/25/20

Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01231542 Org: User:
Start: 05/31/11 End: 12/31/11 Due: 12/31/12

Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine

Phase: N/A Priority: Normal
NCT ID: NCT03836729 Org: User:
Start: 02/11/19 End: 04/30/19 Due: 04/30/20

GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV

Phase: N/A Priority: Normal
NCT ID: NCT03462810 Org: User:
Start: - End: - Due: -

Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)

Phase: N/A Priority: Normal
NCT ID: NCT04982445 Org: User:
Start: 11/18/21 End: 01/31/24 Due: 01/31/25

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02634073 Org: User:
Start: 01/01/16 End: 03/11/16 Due: 03/11/17

Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1

Phase: N/A Priority: Normal
NCT ID: NCT03518060 Org: User:
Start: 06/25/18 End: 05/14/23 Due: 05/14/24

Study to Define Safety and Effectiveness of Dolutegravir (DTG) Use in Human Immunodeficiency Virus (HIV) Positive Pregnant Women

Phase: N/A Priority: Normal
NCT ID: NCT03564613 Org: User:
Start: 11/18/19 End: 10/30/24 Due: 10/30/25

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

Phase: N/A Priority: Normal
NCT ID: NCT02277600 Org: User:
Start: 11/05/14 End: 01/12/15 Due: 01/12/16

A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

Phase: N/A Priority: Normal
NCT ID: NCT06061081 Org: User:
Start: 12/21/23 End: 08/27/24 Due: 08/27/25

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00197145 Org: User:
Start: 07/21/05 End: 09/11/07 Due: 09/11/08

A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01756131 Org: User:
Start: 09/30/10 End: 12/31/12 Due: 12/31/13

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.

Phase: N/A Priority: Normal
NCT ID: NCT01328041 Org: User:
Start: 05/31/11 End: 05/31/15 Due: 05/31/16

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05393271 Org: User:
Start: 10/03/22 End: 04/24/23 Due: 04/24/24

Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.

Phase: N/A Priority: Normal
NCT ID: NCT00945282 Org: User:
Start: 10/20/09 End: 11/28/09 Due: 11/28/10

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

Phase: N/A Priority: Normal
NCT ID: NCT00867152 Org: User:
Start: 04/30/09 End: 05/31/09 Due: 05/31/10